Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

D2, but Not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates ,

Justin P. Meschler, Francis A. Clarkson, Patricia J. Mathews, Allyn C. Howlett and Bertha K. Madras
Journal of Pharmacology and Experimental Therapeutics March 2000, 292 (3) 952-959;
Justin P. Meschler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis A. Clarkson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia J. Mathews
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allyn C. Howlett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bertha K. Madras
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In primates, CB1 cannabinoid receptor agonists produce sedation and psychomotor slowing, in contrast to behavioral stimulation produced by high doses of dopamine receptor agonists. To investigate whether dopamine agonists attenuate the sedative effects of a cannabinoid agonist in monkeys, we compared the effects of D1 or D2 dopamine receptor agonists on spontaneous behavior in three to six cynomolgus monkeys (Macaca fasicularis) alone and after administration of a low dose of the CB1 agonist levonantradol. Alone, the CB1cannabinoid receptor agonist levonantradol (0.01–0.3 mg/kg) induced sedation, ptosis, and decreased locomotor and general activity. Alone, D2-type dopamine agonists quinelorane (0.001–1.0 mg/kg;n = 4) or pergolide (0.01–1.0 mg/kg) or a D1 dopamine agonist 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-3-allyl-[1H]-3-benzazepine (0.3–3.0 mg/kg) produced either no effect or promoted hyperactivity. Thirty minutes after administration of a threshold dose of levonantradol (0.03 mg/kg), D2-type agonists, but not the D1 agonist, precipitated marked sedation, ptosis, and decreased general activity and locomotor activity. These data inducate the following: 1) D2, but not D1 dopamine agonists, potentiate sedation in monkeys treated with a CB1cannabinoid agonist, at doses of agonists that alone do not produce sedation; 2) the threshold dose for cannabinoid-induced sedation is reduced by D2 agonists, but not by a D1dopamine agonist, differentiating D1 and D2dopamine receptor linkage to cannabinoid receptors; and 3) modulation of D2 dopamine receptor activity by a nonsedating dose of a cannabinoid agonist has implications for the pathophysiology and treatment of dopamine-related neuropsychiatric disorders and drug addiction. Cannabinoid agonists and D2 dopamine agonists should be combined with caution.

Footnotes

  • Send reprint requests to: Bertha K. Madras, Ph.D., Division of Neurochemistry, New England Regional Primate Research Center, 1 Pine Hill Dr., Box 9102, Southborough, MA 01772-9102. E-mail:bertha_madras{at}hms.harvard.edu

  • ↵1 This work was supported by Grants DA09462, DA11558, and DA00304 (to B.K.M.); RR00168 (to New England Regional Primate Research Center); and DA03690 and DA05806 (to A.C.H.). Animals used in this study were maintained in accordance with the guidelines of the Committee on Animals of the Harvard Medical School and the “Guide for Care and Use of Laboratory Animals” of the Institute of Laboratory Animal Resources, National Research Council, Department of Health, Education and Welfare Publication No. (NIH)85–23, revised 1985. Research protocols were approved by the Harvard Medical School Institutional Animal Care and Use Committee.

  • ↵2 This work was presented in abstract at the International Union of Pharmacology, Munich, Germany, 1998. Meschler JP, Clarkson FA, Mathews PJ, Howlett AC and Madras BK (1998) Cannabinoid and dopamine agonists interact to produce paradoxical behavioral effects in nonhuman primates. Naunyn-Schmiedeberg's Arch Pharmacol358:R58.

  • ↵3 Current address: Department of Pharmacological and Physiological Science, Saint Louis University, 1402 S. Grand Blvd., St. Louis, MO 63104.

  • Abbreviations:
    SKF 81297
    6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-3-allyl-[1H]-3-benzazepine
    EtOH
    ethanol
    • Received August 11, 1999.
    • Accepted November 24, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 292 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 292, Issue 3
1 Mar 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
D2, but Not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates ,
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

D2, but Not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates ,

Justin P. Meschler, Francis A. Clarkson, Patricia J. Mathews, Allyn C. Howlett and Bertha K. Madras
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 952-959;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

D2, but Not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates ,

Justin P. Meschler, Francis A. Clarkson, Patricia J. Mathews, Allyn C. Howlett and Bertha K. Madras
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 952-959;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Iclepertin (BI 425809) in schizophrenia-related models
  • D1 agonist vs. methylphenidate on PFC working memory
  • Obesity Thwarts Preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics